Straumann reported net revenue of 199 million Swiss francs ($183 million U.S.) for the first quarter of fiscal year 2010, a 3% increase over revenues of 196 million Swiss francs ($181 million) for the same quarter a year ago.
Growth was driven by an increase in the volume of implants sold, with additional impetus coming from new products -- namely, Roxolid and Straumann Allograft -- and CAD/CAM prosthetics, the company noted.
The strength of the Swiss franc against the U.S. dollar and the euro contributed to a negative currency effect of nearly 2% points, with the result that net revenues in Swiss francs increased by almost 2%, the company added.
With continuing uncertainty in the global economy, Straumann said it remains cautious about forecasting when sustainable, underlying growth will return to the market in which it operates. The company assumes that this market will be either flat or will grow in the low single-digit range in 2010.
Copyright © 2010 DrBicuspid.com
